Purinergic Signaling and the Postmenopausal Heart

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-88
SponsorBeth Israel Deaconess Medical Center

About this trial

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Eligibility criteria

Qualifiers

Patients undergoing cardiac surgery under cardiopulmonary bypass.

Disqualifiers

Refusal to participate

Emergency surgery

Pre-existing heart block

Preexisting atrial fibrillation

Trial design

Treatments tested in this trial

  • Gender

Treatment groups

500 Participants
are divided into 2 treatment groups